Tiziana life sciences announces fda ind clearance of intranasal foralumab for the treatment of alzheimer's disease

New york, aug. 15, 2023 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa ) (“tiziana” or the “company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the u.s. food and drug administration (fda) has cleared the investigational new drug (ind) application for intranasal foralumab to be studied in alzheimer's disease. foralumab could be a potentially groundbreaking treatment for alzheimer's disease, given it targets the disease's underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.
TLSA Ratings Summary
TLSA Quant Ranking